Did you mean 100 02 0?
Displaying drugs 676 - 700 of 1437 in total
AVB-001
AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine
Investigational
ISP-001
ISP-001 consists of sleeping beauty transposon-engineered autologous plasmablasts for expression and delivery of alpha-L-iduronidase.
Investigational
BS-001
BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).
Investigational
AL-034
AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.
Investigational
EI-001
Investigational
PTR-01
Investigational
LM-030
Investigational
HH-009
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
Pegtibatinase
Investigational
PF-03758309
PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational
Hypericin
Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.
Investigational
Matched Iupac: … 5,7,11,18,22,24-hexahydroxy-13,16-dimethyloctacyclo[13.11.1.1^{2,10}.0^{3,8}.0^{4,25}.0^{19,27}.0^{21,26 ... }.0^{14,28}]octacosa-1(27),2(28),3,5,7,10,12,14,16,18,21,23,25-tridecaene-9,20-dione …
VXM01
Investigational
QR-313
QR-313 is an antisense oligonucleotide targeting exon 73. It is being investigated for the treatment of dystrophic epidermolysis bullosa.
Investigational
Belzupacap Sarotalocan
Investigational
Ragifilimab
Ragifilimab is under investigation in clinical trial NCT04225039 (Anti-gitr/anti-pd1/stereotactic Radiosurgery, in Recurrent Glioblastoma).
Investigational
Tl-3-093
Experimental
FKB-001
Experimental
NOV-002
NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
Investigational
MDX-018
MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD)...
Investigational
FX06
FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.
Investigational
AGS-004
AGS-004 is a personalized RNA-loaded dendritic cellbased
immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden. Non-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do...
Investigational
RP01
RP01 is a novel anti-IgE immunotherapy for allergic individuals. It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. It could offer benefit to millions of asthma and allergy patients.
Investigational
SNS-032
Investigational
Displaying drugs 676 - 700 of 1437 in total